| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SSTR2 |
| Uniprot No | P30874-1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-369aa |
| 氨基酸序列 | MDMADEPLNGSHTWLSIPFDLNGSVVSTNTSNQTEPYYDLTSNAVLTFIY FVVCIIGLCGNTLVIYVILRYAKMKTITNIYILNLAIADELFMLGLPFLA MQVALVHWPFGKAICRVVMTVDGINQFTSIFCLTVMSIDRYLAVVHPIKS AKWRRPRTAKMITMAVWGVSLLVILPIMIYAGLRSNQWGRSSCTINWPGE SGAWYTGFIIYTFILGFLVPLTIICLCYLFIIIKVKSSGIRVGSSKRKKS EKKVTRMVSIVVAVFIFCWLPFYIFNVSSVSMAISPTPALKGMFDFVVVL TYANSCANPILYAFLSDNFKKSFQNVLCLVKVSGTDDGERSDSKQDKSRL NETTETQRTLLNGDLQTSI |
| 预测分子量 | 43 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SSTR2重组蛋白的3-4篇假设参考文献示例，格式为文献名称、作者及摘要概括(注：以下内容为示例，实际文献需通过学术数据库查询)：
---
1. **文献名称**: "High-Yield Expression and Purification of Recombinant Human SSTR2 for Structural Studies"
**作者**: Zhang Y, et al.
**摘要**: 该研究报道了在昆虫细胞系统中高效表达和纯化重组人源SSTR2的方法，并通过质谱和圆二色谱验证了蛋白的完整性和正确折叠，为后续受体结构功能研究奠定基础。
2. **文献名称**: "Targeted Delivery of Anticancer Drugs via SSTR2-Conjugated Nanoparticles in Neuroendocrine Tumors"
**作者**: Lee S, et al.
**摘要**: 开发了一种基于重组SSTR2的靶向纳米递送系统，体外实验显示其对SSTR2高表达肿瘤细胞具有显著选择性，并增强化疗药物的细胞内摄取。
3. **文献名称**: "Functional Characterization of SSTR2 Agonists Using a Recombinant Cell-Based Assay System"
**作者**: Müller A, et al.
**摘要**: 利用稳定表达重组SSTR2的HEK293细胞系，建立了一种高通量筛选模型，用于评估SSTR2激动剂的效力和信号转导机制。
4. **文献名称**: "Cryo-EM Structure of SSTR2 in Complex with a Synthetic Peptide Antagonist"
**作者**: Wang X, et al.
**摘要**: 通过冷冻电镜解析了重组SSTR2与合成拮抗肽的复合物结构，揭示了配体结合口袋的关键残基，为设计靶向药物提供结构依据。
---
**建议**：如需真实文献，可通过PubMed或Google Scholar搜索关键词“SSTR2 recombinant protein expression”、“SSTR2 structure”或“SSTR2 targeted therapy”获取最新研究。经典文献可参考Reubi JC和Kwekkeboom DJ团队关于SSTR2在肿瘤靶向治疗中的研究。
SSTR2 (somatostatin receptor subtype 2) is a G protein-coupled receptor (GPCR) that binds somatostatin, a regulatory peptide hormone involved in inhibiting the secretion of various hormones, including growth hormone, insulin, and glucagon. It plays a critical role in modulating cellular proliferation, neurotransmission, and endocrine signaling. SSTR2 is highly expressed in neuroendocrine tissues, certain cancers (e.g., neuroendocrine tumors, pituitary adenomas), and immune cells, making it a key target for therapeutic and diagnostic applications.
Recombinant SSTR2 proteins are engineered versions of the receptor, typically produced in vitro using expression systems like mammalian cells, bacteria, or insect cells. These proteins retain the ligand-binding and functional properties of native SSTR2. enabling researchers to study receptor-ligand interactions, signaling pathways, and structural features. Recombinant SSTR2 is often utilized in drug discovery to screen and optimize synthetic somatostatin analogs (e.g., octreotide, lanreotide) or radiolabeled tracers for cancer imaging (e.g., Ga-68 DOTATATE PET scans). Additionally, it aids in understanding receptor dysregulation in diseases and developing targeted therapies.
The structural characterization of SSTR2. including its extracellular domains critical for ligand binding and transmembrane regions involved in signal transduction, has been a focus of biomedical research. Its overexpression in tumors has also driven interest in SSTR2-targeted theranostics, combining diagnostic imaging and radiotherapy. Overall, recombinant SSTR2 serves as a vital tool for advancing both basic science and clinical applications in oncology, endocrinology, and molecular pharmacology.
×
